Multi-agonist therapies targeting combinations of gut hormone receptors—such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors—represent a novel approach to enhancing metabolic outcomes in obesity treatment. This evidence concerns the gene GLP1R and obesity disorder.